Results 131 to 140 of about 11,774 (158)

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. [PDF]

Diabetes Obes Metab
Bhattachar S, Tham LS, Tidemann-Miller B, Ibriga H, Qu H, Briere DA, Haupt A, Mather KJ, Pratt E.   +8 more
europepmc   +1 more source

A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy. [PDF]

Pharmaceuticals (Basel)
Lee S, Song H, Kwon Y.
europepmc   +1 more source

Gut Peptide Alterations in Type 2 Diabetes and Obesity: A Narrative Review. [PDF]

Curr Obes Rep
Tzeravini E, Simati S, Anastasiou IA, Dalamaga M, Kokkinos A.   +4 more
europepmc   +1 more source

Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. [PDF]

J Med Chem
Fischer Munch H, Just R, Mosolff Mathiesen J, Eriksson PO, Skodborg Villadsen J, Vestergaard B, Deryabina M, Demmer O, Skarbaliene J, Hamprecht DW, Rist W, Baader-Pagler T, Grube A, Heim-Riether A, Giehm L.   +14 more
europepmc   +1 more source

Management of Obese Patients with Cardiovascular Disease with Emerging Weight-Lowering Drugs: A Narrative Review. [PDF]

Biomedicines
Ciarloni A, Salvio G, Bordoni M, Giacchetti G, Balercia G.   +4 more
europepmc   +1 more source

Pancreatic hypersecretion of amyloid-forming human amylin dysregulates the neuro-immune axis and B cell development in a model of type-2 diabetes. [PDF]

Neurobiol Dis
Winford ED, Shahidehpour R, Dressman D, Turchan-Cholewo J, Cotter KM, Leibold N, Ujas TA, Britsch DRS, Mercurio D, Colson MK, Verma N, Despa S, Bachstetter AD, Despa F, Stowe AM.   +14 more
europepmc   +1 more source